AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22806681 — intervention group
Group type: COMPARATOR
Intervention: PR48 (placebo)
Number of subjects: 662
Study 22806681 — intervention group
Group type: EXPERIMENTAL
Intervention: telaprevir treatment
Number of subjects: 662
Study 22806681 — intervention group
Group type: EXPERIMENTAL
Intervention: non-SVR patients
Number of subjects: 662
Study 19884596 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention from nursery discharge until age 3 years
Number of subjects: 985
Study 19884596 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention (NI)
Number of subjects: 985
Study 17323793 — intervention group
Group type: EXPERIMENTAL
Intervention: Deximune soft‐gelatin capsules (200 mg CsA)
Number of subjects: 24
Study 17323793 — intervention group
Group type: COMPARATOR
Intervention: Sandimmune Neoral (200 mg CsA)
Number of subjects: 24
Study 17323793 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations (Deximune and Sandimmune)
Number of subjects: 24
Study 15172146 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermoluminescent dosimeters (TLD) used for in vivo dosimetry
Number of subjects: 429
Study 15172146 — intervention group
Group type: EXPERIMENTAL
Intervention: TLD measurements
Number of subjects: 429
Study 11597376 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical GM-CSF mouthwashes
Number of subjects: 31
Study 11597376 — intervention group
Group type: COMPARATOR
Intervention: Combined topical use of antiseptic agent (povidone-iodine) and amphotericin B (AA)
Number of subjects: 31
Study 10599595 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte reducing filter (LRF) added to FKDB
Number of subjects: 23
Study 10599595 — intervention group
Group type: COMPARATOR
Intervention: Filtered knee drain blood (FKDB) without LRF
Number of subjects: 23
Study 10599595 — intervention group
Group type: EXPERIMENTAL
Intervention: FKDB with resuspended erythrocytes
Number of subjects: 23
Study 8573016 — intervention group
Group type: EXPERIMENTAL
Intervention: Zone I eyes
Number of subjects: 3
Study 8573016 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional eyes
Number of subjects: 3
Study 8573016 — intervention group
Group type: EXPERIMENTAL
Intervention: Zone II eyes
Number of subjects: 3
Study 8573016 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of prominent iris vessels at 34 to 35 weeks
Number of subjects: 3
Study 8573016 — intervention group
Group type: EXPERIMENTAL
Intervention: Degree of early retinal vessel development
Number of subjects: 3
Study 1743806 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg Parlodel-SRO administered in two intakes (b.i.d.)
Number of subjects: 18
Study 1743806 — intervention group
Group type: COMPARATOR
Intervention: 30 mg Parlodel-SRO administered in one dose (once daily)
Number of subjects: 18
Study 1743806 — intervention group
Group type: COMPARATOR
Intervention: 30 mg Parlodel-SRO administered in three intakes (t.i.d.)
Number of subjects: 18
Study 6174865 — intervention group
Group type: COMPARATOR
Intervention: MOPP alone (mechlorethamine, vincristine, procarbazine, and prednisone)
Number of subjects: 75
Study 6174865 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP alternating with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine)
Number of subjects: 75
Study 6174865 — intervention group
Group type: COMPARATOR
Intervention: MOPP alone
Number of subjects: 75
Study 6174865 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP plus ABVD
Number of subjects: 75
Study 31027422 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine extended release treatment in MEM‐MD‐91 trial
Number of subjects: 517
Study 31027422 — intervention group
Group type: COMPARATOR
Intervention: Memantine extended release treatment in MEM‐MD‐68 trial
Number of subjects: 517
Study 31027422 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine extended release treatment in MEM‐MD‐69 trial
Number of subjects: 517
Study 30012391 — intervention group
Group type: EXPERIMENTAL
Intervention: Thai instrumental folk music listening
Number of subjects: 120
Study 30012391 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 27618090 — intervention group
Group type: COMPARATOR
Intervention: Healthy diet group (n = 79)
Number of subjects: 298
Study 27618090 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g-oats group (n = 80)
Number of subjects: 298
Study 27618090 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 g-oats group (n = 79)
Number of subjects: 298
Study 24006148 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular aneurysm repair (EVAR)
Number of subjects: 0
Study 24006148 — intervention group
Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 0
Study 23328283 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose plus live combined Bacillus subtilis and Enterococcus faecium capsules for 14 days, followed by only Bacillus subtilis and Enterococcus faecium capsules for 14 days
Number of subjects: 216
Study 23328283 — intervention group
Group type: COMPARATOR
Intervention: Lactulose plus placebo for 2 weeks, followed by only placebo for 2 weeks
Number of subjects: 216
Study 19810663 — intervention group
Group type: EXPERIMENTAL
Intervention: WFG LASIK
Number of subjects: 11
Study 19810663 — intervention group
Group type: COMPARATOR
Intervention: WFG PRK
Number of subjects: 11
Study 18060813 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin therapy
Number of subjects: 98
Study 18060813 — intervention group
Group type: COMPARATOR
Intervention: Extended patient counseling
Number of subjects: 98
Study 18060813 — intervention group
Group type: COMPARATOR
Intervention: Standard patient counseling
Number of subjects: 98
Study 16044668 — intervention group
Group type: EXPERIMENTAL
Intervention: Talnetant (SB‐223412)
Number of subjects: 0
Study 12848716 — intervention group
Group type: EXPERIMENTAL
Intervention: Periotest readings
Number of subjects: 101
Study 12848716 — intervention group
Group type: COMPARATOR
Intervention: Traditional special tests (mobility testing, percussion sounds, radiographs)
Number of subjects: 101
Study 10097992 — intervention group
Group type: EXPERIMENTAL
Intervention: High-functioning autistic adults
Number of subjects: 10
Study 10097992 — intervention group
Group type: COMPARATOR
Intervention: Normal adults (control group)
Number of subjects: 10
Study 8630669 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin with CCBs
Number of subjects: 0
Study 8630669 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin without CCBs
Number of subjects: 0
Study 8630669 — intervention group
Group type: COMPARATOR
Intervention: CCBs
Number of subjects: 0
Study 1360337 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 40
Study 1360337 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 40
Study 1360337 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium
Number of subjects: 40
Study 6200129 — intervention group
Group type: EXPERIMENTAL
Intervention: iopamidol
Number of subjects: 40
Study 6200129 — intervention group
Group type: COMPARATOR
Intervention: Cardio‐Conray
Number of subjects: 40
Study 30053159 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (EVE) at 4.5 mg/m2/day in EXIST-1 and 10 mg/day in EXIST-2
Number of subjects: 223
Study 30053159 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (EVE)
Number of subjects: 223
Study 29924641 — intervention group
Group type: EXPERIMENTAL
Intervention: 34G × 3.5 mm needle
Number of subjects: 77
Study 29924641 — intervention group
Group type: COMPARATOR
Intervention: 32G × 4 mm needle
Number of subjects: 77
Study 29924641 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both needles
Number of subjects: 77
Study 29924641 — intervention group
Group type: EXPERIMENTAL
Intervention: Both needles
Number of subjects: 77
Study 27502818 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 0
Study 27502818 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo group)
Number of subjects: 0
Study 25172950 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 nmol l(‐1))
Number of subjects: 0
Study 25172950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21358707 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (selective serotonin-uptake inhibitor) administered for 7 days
Number of subjects: 29
Study 21358707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 20673361 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical insufficiency group (CI)
Number of subjects: 79
Study 20673361 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 79
Study 18343637 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus johnsonii La1 (La1)
Number of subjects: 295
Study 18343637 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice/heat-killed La1 (CB)
Number of subjects: 295
Study 18343637 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice/Lactobacillus johnsonii La1 (CB/La1)
Number of subjects: 295
Study 18343637 — intervention group
Group type: COMPARATOR
Intervention: Placebo juice/heat-killed La1 (control)
Number of subjects: 295
Study 16182023 — intervention group
Group type: EXPERIMENTAL
Intervention: High-velocity, low-amplitude chiropractic adjustments (group 1)
Number of subjects: 60
Study 16182023 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical-force, manually-assisted chiropractic adjustments (group 2)
Number of subjects: 60
Study 12879833 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment via general practice
Number of subjects: 0
Study 12879833 — intervention group
Group type: COMPARATOR
Intervention: Recruitment via local newspaper article
Number of subjects: 0
Study 10319076 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive diet and exercise recommendations, lipid-lowering drugs according to NCEP guidelines
Number of subjects: 152
Study 10319076 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug therapy
Number of subjects: 152
Study 10319076 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary compliance
Number of subjects: 152
Study 10319076 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up duration
Number of subjects: 152
Study 10319076 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight change
Number of subjects: 152
Study 10319076 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly exercise
Number of subjects: 152
Study 8732324 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (nitrendipine combined with enalapril and/or hydrochlorothiazide)
Number of subjects: 421
Study 8732324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 421
Study 8732324 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 421
Study 8517385 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg, titrated to a maximum of 40 mg/day
Number of subjects: 550
Study 8517385 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 10 mg, titrated to a maximum of 40 mg/day
Number of subjects: 550
Study 8517385 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin and Pravastatin
Number of subjects: 550
Study 3127574 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural surfactant preparation consisting of lipids extracted from calf lung lavage
Number of subjects: 72
Study 3127574 — intervention group
Group type: COMPARATOR
Intervention: Control group (no surfactant)
Number of subjects: 72
Study 30024827 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoster Virus Live (ZVL)
Number of subjects: 0
Study 30024827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26860807 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (CHM) as maintenance therapy
Number of subjects: 106
Study 26860807 — intervention group
Group type: COMPARATOR
Intervention: Best supporting care (BSC)
Number of subjects: 106
Study 25130788 — intervention group
Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide levels in AKI group
Number of subjects: 390
Study 25130788 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer levels in AKI group
Number of subjects: 390
Study 25130788 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein levels in AKI group
Number of subjects: 390
Study 25130788 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelial cell-selective adhesion molecule levels in AKI group
Number of subjects: 390
Study 25130788 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiponectin levels in AKI group
Number of subjects: 390
Study 25130788 — intervention group
Group type: EXPERIMENTAL
Intervention: Von Willebrand factor levels in AKI group
Number of subjects: 390
Study 25130788 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C levels in AKI group
Number of subjects: 390
Study 25130788 — intervention group
Group type: COMPARATOR
Intervention: Chemokine (C-C motif) ligand 23 levels in no-AKI group
Number of subjects: 390
Study 23233721 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine
Number of subjects: 414
Study 23233721 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil
Number of subjects: 414
Study 21810269 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT)
Number of subjects: 60
Study 21810269 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 60
Study 19342701 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (300 microg/d as high-Se yeast)
Number of subjects: 42
Study 19342701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 16428753 — intervention group
Group type: EXPERIMENTAL
Intervention: ACAM2010 vaccine (5 x 10^9 CFU)
Number of subjects: 49
Study 16428753 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 49
Study 15571534 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine glove use by healthcare workers for all residents without contact-isolation precautions
Number of subjects: 667
Study 15571534 — intervention group
Group type: COMPARATOR
Intervention: Contact-isolation precautions for residents with vancomycin-resistant enterococci or methicillin-resistant Staphylococcus aureus
Number of subjects: 667
Study 11264331 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpretive therapy
Number of subjects: 89
Study 11264331 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive therapy
Number of subjects: 89
Study 10446037 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/day of alpha-tocopherol (n = 27)
Number of subjects: 39
Study 10446037 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 12)
Number of subjects: 39
Study 8005274 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic progesterone (P) administration (12.5 mg IM on days 2 and 7) during the artificial follicular phase (Group A)
Number of subjects: 32
Study 8005274 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic progesterone (P) administration (6.25 mg on days 3, 4, and 5) during the artificial follicular phase (Group B)
Number of subjects: 32
Study 8005274 — intervention group
Group type: COMPARATOR
Intervention: Standard preparatory cycles without P supplementation (Group C)
Number of subjects: 32
Study 2643039 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation
Number of subjects: 673
Study 2643039 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation
Number of subjects: 673
Study 4568265 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids for 7 to 8 days
Number of subjects: 135
Study 4568265 — intervention group
Group type: COMPARATOR
Intervention: Control group (no steroids)
Number of subjects: 135
Study 29393061 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated repetitive simulated annealing molecular dynamics (AR‐SAMD) approach
Number of subjects: 0
Study 29393061 — intervention group
Group type: EXPERIMENTAL
Intervention: Dead End Elimination cum Monte Carlo based optimization tool
Number of subjects: 0
Study 26253032 — intervention group
Group type: EXPERIMENTAL
Intervention: PPC-M1 paired-pulse stimulation at 80% RMT preconditioning
Number of subjects: 0
Study 26253032 — intervention group
Group type: EXPERIMENTAL
Intervention: PPC-PMv-M1 stimulation
Number of subjects: 0
Study 26253032 — intervention group
Group type: COMPARATOR
Intervention: PMv-M1 paired-pulse stimulation
Number of subjects: 0
Study 26253032 — intervention group
Group type: COMPARATOR
Intervention: PPC-M1 paired-pulse stimulation
Number of subjects: 0
Study 24382580 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic therapy (ARMin exoskeleton robot)
Number of subjects: 77
Study 24382580 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 77
Study 23477205 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy products (932 mg Ca; n = 19)
Number of subjects: 37
Study 23477205 — intervention group
Group type: COMPARATOR
Intervention: Calcium citrate tablets (1000 mg calcium/day; n = 18)
Number of subjects: 37
Study 20942666 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine plus tenofovir–emtricitabine
Number of subjects: 241
Study 20942666 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir-boosted lopinavir plus tenofovir–emtricitabine
Number of subjects: 241
Study 18070045 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone controlled release (Oxy-CR), 5-10 mg, q12 h/day
Number of subjects: 116
Study 18070045 — intervention group
Group type: COMPARATOR
Intervention: Placebo, q12 h/day
Number of subjects: 116
Study 16152994 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guided IJVC insertion (group B)
Number of subjects: 60
Study 16152994 — intervention group
Group type: COMPARATOR
Intervention: Blind IJVC insertion (group A)
Number of subjects: 60
Study 14657879 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (3.7 g n‐3 PUFAs per day)
Number of subjects: 98
Study 14657879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 10206045 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser treatment
Number of subjects: 21
Study 10206045 — intervention group
Group type: COMPARATOR
Intervention: Er:YAG laser treatment
Number of subjects: 21
Study 2164204 — intervention group
Group type: EXPERIMENTAL
Intervention: Polychemotherapy combined with beta‐ and gamma‐interferon
Number of subjects: 40
Study 2164204 — intervention group
Group type: COMPARATOR
Intervention: Polychemotherapy without interferon (control group)
Number of subjects: 40
Study 2164204 — intervention group
Group type: EXPERIMENTAL
Intervention: Polychemotherapy with interferon
Number of subjects: 40
Study 350263 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical atenolol (2% 3 times a day)
Number of subjects: 8
Study 350263 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical pilocarpine (2% 3 times a day)
Number of subjects: 8
Study 350263 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 2% pilocarpine and 2% atenolol administered 15 minutes apart (3 times a day)
Number of subjects: 8
Study 350263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30890122 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week exercise program using stationary bicycles (Mini-bike)
Number of subjects: 60
Study 30890122 — intervention group
Group type: COMPARATOR
Intervention: 10-min limbering exercise for 8 weeks (Control)
Number of subjects: 60
Study 27876220 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief communication skills training module for breaking bad news (BBN)
Number of subjects: 66
Study 26512597 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-CT scan at 9 months (PET-CT9) after the start of radiation treatment
Number of subjects: 92
Study 26512597 — intervention group
Group type: COMPARATOR
Intervention: Standard follow-up without PET-CT9 (Control Group B)
Number of subjects: 92
Study 25551791 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based quality improvement (QI) system with indicator-based performance feedback and educational outreach visits
Number of subjects: 18
Study 22843114 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate aerobic exercise 45-60 min, 4 days per week, through 36 weeks gestation
Number of subjects: 62
Study 22843114 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 62
Study 19242343 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 40,000 IU once weekly, subcutaneously (group A)
Number of subjects: 60
Study 19242343 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 40,000 IU once weekly, intravenously (group B)
Number of subjects: 60
Study 19242343 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 15,000 IU every other day, subcutaneously (group C)
Number of subjects: 60
Study 19242343 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 15,000 IU every other day, intravenously (group D)
Number of subjects: 60
Study 19242343 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 40,000 IU on day 1 and 3, subcutaneously (group E)
Number of subjects: 60
Study 19242343 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 40,000 IU on day 1 and 3, intravenously (group F)
Number of subjects: 60
Study 19242343 — intervention group
Group type: EXPERIMENTAL
Intervention: All dosing regimens of epoetin alfa
Number of subjects: 60
Study 19242343 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events reported
Number of subjects: 60
Study 17558821 — intervention group
Group type: EXPERIMENTAL
Intervention: Degree of craving measured by the Questionnaire on Smoking Urges
Number of subjects: 34
Study 17558821 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarettes smoked per day
Number of subjects: 34
Study 15679127 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 mg of tetracaine
Number of subjects: 30
Study 15679127 — intervention group
Group type: COMPARATOR
Intervention: 6.0 mg of tetracaine
Number of subjects: 30
Study 12175983 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused breast skills workshop (2 hours)
Number of subjects: 124
Study 12175983 — intervention group
Group type: COMPARATOR
Intervention: Traditional ambulatory teaching (4 hours)
Number of subjects: 124
Study 9615801 — intervention group
Group type: EXPERIMENTAL
Intervention: MTH‐68/B vaccine treatment
Number of subjects: 84
Study 9615801 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 84
Study 8087786 — intervention group
Group type: EXPERIMENTAL
Intervention: Conformal three-dimensional (3D) radiation treatment
Number of subjects: 0